Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Clinical trial NCT04726332 · TERMINATED

Trial details

NCT number: NCT04726332
Sponsor: Exelixis
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasm Malignant Epithelial Ovarian Cancer Triple Negative Breast Cancer Hormone Receptor Positive Breast Carcinoma Metastatic Castration-resistant Prostate Cancer

Start date: 2021-02-10
Primary completion: 2024-05-02
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.